Table 3.
|
Immunisation |
ITNs |
Anti- malaria drugs |
ANC |
Childbirth |
ARVs |
FP |
TB |
---|---|---|---|---|---|---|---|---|
Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | |
Gross benefits by urban-rural residence | ||||||||
Urban |
457.3 (140.0) |
176.2 (381.1) |
13.7 (125.8) |
81.3 (1,224.2) |
4.3 (179.4) |
0 |
0 |
14.3 (598.5) |
Rural |
419.7 (183.7) |
3.3 (57.5) |
33.7 (246.7) |
11.0 (181.1) |
10.3 (278.4) |
0 |
0 |
159.8 (2,576.3) |
Kruskal-Wallis (p-value) |
45.2 (.0001) |
278.8 (.0001) |
8.2 (.004) |
2.9 (.08) |
0.47 (.49) |
- |
- |
4.8 (.03) |
Gross benefits by gender | ||||||||
Males |
463.4 (130.3) |
71.9 (258.4) |
16.2 (141.5) |
NA |
NA |
0 |
0 |
69.1 (1,609.0) |
Females |
419.7 (183.6) |
116.5 (321.1) |
28.5 (224.9) |
NA |
NA |
0 |
0 |
88.1 (1,914.8) |
Kruskal-Wallis (p-value) |
60.3 (.0001) |
18.6 (.0001) |
3.2 (.07) |
18.7 (.0001) |
2.6 (.10) |
- |
- |
0.02 (.88) |
Gross benefits by SES | ||||||||
Quintile 1 |
398.3 (201.4) |
40.9 (198.1) |
41.4 (226.3) |
8.8 (170.6) |
11.0 (287.6) |
0 |
0 |
76.0 (1,377.3) |
Quintile 2 |
447.9 (152.9) |
83.0 (276.1) |
12.8 (124.3) |
34.4 (535.0) |
0 |
0 |
0 |
109.5 (2,134.7) |
Quintile 3 |
447.9 (152.9) |
90.8 (287.5) |
24.5 (281.9) |
55.6 (1,374.4) |
12.3 (303.2) |
0 |
0 |
164.5 (2,865.3) |
Quintile 4 |
450.1 (150.0) |
154.1 (361.3) |
19.7 (139.0) |
102.0 (1,207.9) |
12.3 (304.2) |
0 |
0 |
41.5 (1,018.1) |
Quintile 5 |
460.4 (135.2) |
124.2 (330.1) |
15.0 (134.5) |
53.5 (825.0) |
0 |
0 |
0 |
0 |
Kruskal-Wallis (p-value) |
64.5 (.0003) |
56.7 (.0001) |
15.3 (.004) |
20.3 (.0004) |
2.0 (.73) |
- |
- |
2.1 (.72) |
Concentration index | 0.03 | 0.19 | −0.16 | 0.25 | −0.11 | - | - | −0.22 |